Alta Capital Management LLC Buys 1,253 Shares of IDEXX Laboratories, Inc. $IDXX

Alta Capital Management LLC raised its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.0% during the second quarter, HoldingsChannel.com reports. The fund owned 22,143 shares of the company’s stock after acquiring an additional 1,253 shares during the quarter. Alta Capital Management LLC’s holdings in IDEXX Laboratories were worth $11,876,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Mutual Advisors LLC bought a new stake in IDEXX Laboratories in the second quarter valued at $244,000. Harbour Investments Inc. grew its position in IDEXX Laboratories by 27.3% in the second quarter. Harbour Investments Inc. now owns 98 shares of the company’s stock valued at $53,000 after acquiring an additional 21 shares during the period. AEGON ASSET MANAGEMENT UK Plc grew its position in IDEXX Laboratories by 50.6% during the 2nd quarter. AEGON ASSET MANAGEMENT UK Plc now owns 48,308 shares of the company’s stock worth $25,887,000 after acquiring an additional 16,237 shares during the last quarter. Aries Wealth Management grew its position in IDEXX Laboratories by 2.5% during the 2nd quarter. Aries Wealth Management now owns 3,172 shares of the company’s stock worth $1,701,000 after acquiring an additional 76 shares during the last quarter. Finally, Sagespring Wealth Partners LLC grew its position in IDEXX Laboratories by 38.7% during the 2nd quarter. Sagespring Wealth Partners LLC now owns 756 shares of the company’s stock worth $406,000 after acquiring an additional 211 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Stock Up 0.4%

Shares of IDXX opened at $639.15 on Thursday. The firm has a market capitalization of $51.13 billion, a price-to-earnings ratio of 53.22, a PEG ratio of 4.12 and a beta of 1.58. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. The business’s fifty day moving average price is $640.70 and its two-hundred day moving average price is $546.36. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, August 4th. The company reported $3.63 EPS for the quarter, beating analysts’ consensus estimates of $3.28 by $0.35. The firm had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same period last year, the company earned $2.44 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on IDXX shares. Wall Street Zen lowered IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Sunday, September 28th. JPMorgan Chase & Co. increased their price target on IDEXX Laboratories from $550.00 to $675.00 and gave the stock an “overweight” rating in a research report on Monday, August 4th. Stifel Nicolaus set a $640.00 price target on IDEXX Laboratories in a research report on Monday, August 4th. Jefferies Financial Group started coverage on IDEXX Laboratories in a research report on Tuesday, July 1st. They set a “buy” rating and a $625.00 price target on the stock. Finally, Morgan Stanley increased their price target on IDEXX Laboratories from $722.00 to $765.00 and gave the stock an “overweight” rating in a research report on Friday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $656.50.

Insider Transactions at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 7,143 shares of the stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $630.43, for a total value of $4,503,161.49. Following the transaction, the executive vice president owned 18,007 shares of the company’s stock, valued at $11,352,153.01. This represents a 28.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Michael Lane sold 8,411 shares of the stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $627.74, for a total value of $5,279,921.14. Following the completion of the transaction, the executive vice president directly owned 7,132 shares in the company, valued at approximately $4,477,041.68. This trade represents a 54.11% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 54,057 shares of company stock worth $34,293,468. Corporate insiders own 0.98% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.